Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse

Sponsor
ARCAGY/ GINECO GROUP
Study ID
NCT04015739
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Assessing the safety and efficacy of the bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patient with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at least one previous line of platinum-taxane chemotherapy, and present with platinum resistant disease (PRR) or platinum-sensitive relapse (PSR), whatever the line of chemotherapy given at relapse.

Key Dates

Start date
Mar 1, 2019
Status verified
Aug 2022
Primary completion
Jun 30, 2020
Completion
Jan 29, 2024

Study Design

Enrollment
74 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab, Olaparib and Durvalumab
    Single arm study

Primary Outcome Measure

Safety and tolerability of the PRR cohort: Rate of clinical and radiological non-progressive disease [ Time Frame: At 3 months ]

Related Studies